Table 4. Cox regression analysis (PFS).
| Variables | Univariate Cox regression model | Multivariate Cox regression model | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Sex (male vs. female) | 0.923 | 0.531–1.606 | 0.778 | ||||
| Age (years, <65 vs. ≥65) | 1.106 | 0.679–1.803 | 0.685 | ||||
| Disease site | |||||||
| Cardia | 1.0 | ||||||
| Gastric fundus | – | – | – | ||||
| Gastric body | 1.411 | 0.762–2.613 | 0.274 | ||||
| Gastric antrum | 1.068 | 0.584–1.953 | 0.831 | ||||
| Histology | |||||||
| Differentiation (1= moderately; 2= poorly) | 1.274 | 0.461–3.520 | 0.641 | ||||
| Site of metastases | |||||||
| Liver | 0.974 | 0.592–1.603 | 0.918 | ||||
| Lung | 0.975 | 0.389–2.422 | 0.957 | ||||
| Retroperitoneal lymph node metastasis | 1.163 | 0.710–1.907 | 0.549 | ||||
| Others | 1.575 | 0.962–2.580 | 0.071 | ||||
| Therapy (aTS vs. SOX) | 0.610 | 0.372–0.999 | 0.050 | 0.605 | 0.369–0.992 | 0.047 | |
| Cycles of first line chemotherapy (>2 vs. 2) | 0.230 | 0.117–0.455 | 0.000 | 0.228 | 0.116–0.452 | 0.000 | |
PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; aTS, albumin-bound paclitaxel and S-1; SOX, standard S-1 and oxaliplatin.